Russell Investments Group Ltd. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Russell Investments Group Ltd. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,208 shares of the biopharmaceutical company's stock after purchasing an additional 7,944 shares during the quarter. Russell Investments Group Ltd. owned about 0.12% of Regeneron Pharmaceuticals worth $97,690,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $28,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 0.7 %

Regeneron Pharmaceuticals stock traded up $3.70 during mid-day trading on Friday, hitting $550.09. The company's stock had a trading volume of 452,359 shares, compared to its average volume of 704,420. Regeneron Pharmaceuticals, Inc. has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $60.14 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The stock's fifty day moving average is $662.80 and its two-hundred day moving average is $758.54.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business earned $11.86 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.